Click on a field for details on how to access that data via Web API, Excel, or CSV File Download.
| Open Price | |
| High Price | |
| Low Price | |
| Close Price | |
| Change | |
| Percent Change | |
| Volume |
| Avg Daily Volume | 192,193 |
| 52 Week High | $0.55 |
| 52 Week Low | $0.25 |
| Target Price | $3.88 |
| Ticker | IGC:UA |
| Composite Ticker | IGC:US |
| Security Name | IGC Pharma Inc |
| Type | Ordinary Shares |
| Class | IGC |
| Currency | USD |
| Round Lot Size | 100 |
| Primary | Yes |
| Delisted | No |
| ETF | No |
| Market Category | Common Stock |
| Market Sector | N/A |
| Exchange Symbol | ^USCOMP |
| Exchange Name | US COMPOSITE |
| Exchange City | N/A |
| Exchange Country | UNITED STATES OF AMERICA |
| Exchange Website | N/A |
| FIGI | BBG000NSSM49 |
| Composite FIGI | BBG000NSSLY8 |
| Share Class FIGI | BBG001SQQKX0 |
| FIGI Unique ID | EQ0000000002432755 |
| Dividend | N/A |
| Dividend Rate | N/A |
| Trailing Dividend Yield | 0.00% |
| 5-year Average Dividend Yield | 0.00% |
| Dividend Ex Date | 2013-04-19 |
| Beta | 0.6413 |
| 1-year beta | 0.4465 |
| 3-year beta | 0.6413 |
| 5-year beta | 1.231 |
| 7-year beta | 1.7646 |
| 10-year beta | 1.7292 |
IGC Pharma, Inc., a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development. It also markets Holief, a wellness brand that targets women experiencing premenstrual syndrome and menstrual cramps. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.
